ATE326236T1 - Hpv-e7 zur behandlung von menschlichem papillomavirus - Google Patents

Hpv-e7 zur behandlung von menschlichem papillomavirus

Info

Publication number
ATE326236T1
ATE326236T1 AT01950461T AT01950461T ATE326236T1 AT E326236 T1 ATE326236 T1 AT E326236T1 AT 01950461 T AT01950461 T AT 01950461T AT 01950461 T AT01950461 T AT 01950461T AT E326236 T1 ATE326236 T1 AT E326236T1
Authority
AT
Austria
Prior art keywords
subject
type
papilloma virus
human papilloma
hpv
Prior art date
Application number
AT01950461T
Other languages
English (en)
Inventor
John Neefe
Stephen Goldstone
Mark Winnett
Marvin Siegel
Leslie Boux
Original Assignee
Stressgen Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stressgen Biotechnologies Corp filed Critical Stressgen Biotechnologies Corp
Application granted granted Critical
Publication of ATE326236T1 publication Critical patent/ATE326236T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
AT01950461T 2000-06-26 2001-06-26 Hpv-e7 zur behandlung von menschlichem papillomavirus ATE326236T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21420200P 2000-06-26 2000-06-26

Publications (1)

Publication Number Publication Date
ATE326236T1 true ATE326236T1 (de) 2006-06-15

Family

ID=22798190

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01950461T ATE326236T1 (de) 2000-06-26 2001-06-26 Hpv-e7 zur behandlung von menschlichem papillomavirus

Country Status (27)

Country Link
US (4) US20020110566A1 (de)
EP (1) EP1296711B1 (de)
JP (1) JP2004512264A (de)
KR (2) KR20080075560A (de)
CN (1) CN100441223C (de)
AT (1) ATE326236T1 (de)
AU (3) AU2001271449B2 (de)
BR (1) BR0111956A (de)
CA (1) CA2413543A1 (de)
CY (1) CY1105389T1 (de)
CZ (1) CZ20024154A3 (de)
DE (1) DE60119734T2 (de)
DK (1) DK1296711T3 (de)
EE (1) EE200200709A (de)
ES (1) ES2263637T3 (de)
HR (1) HRP20021015A2 (de)
HU (1) HUP0301308A3 (de)
IL (1) IL153474A0 (de)
MX (1) MXPA02012858A (de)
NO (1) NO20026044L (de)
NZ (1) NZ523408A (de)
PL (1) PL359930A1 (de)
PT (1) PT1296711E (de)
RU (1) RU2282461C2 (de)
SK (1) SK18362002A3 (de)
WO (1) WO2002000242A2 (de)
ZA (1) ZA200210211B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
EP1196772A2 (de) 1999-07-08 2002-04-17 Stressgen Biotechnologies Corporation Induktion einer th1-vermittelten immunantwort in vitro
US20050244434A1 (en) * 1999-08-12 2005-11-03 Cohen David I Tat-based tolerogen compositions and methods of making and using same
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
HRP20021015A2 (en) * 2000-06-26 2004-02-29 Stressgen Biotechnologies Corp Human papilloma virus treatment
EP1363938B1 (de) 2000-08-03 2013-12-11 Johns Hopkins University An endoplasmatischen reticulums chaperonprotein gebundenes antigen als molekulärimpfstoff
MXPA03006971A (es) 2001-02-05 2004-05-05 Stressgen Biotechnologies Corp Tratamiento del virus de hepatitis b.
US6649402B2 (en) * 2001-06-22 2003-11-18 Wisconsin Alumni Research Foundation Microfabricated microbial growth assay method and apparatus
AU2003284239B2 (en) * 2002-10-21 2008-08-21 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease
ATE503492T1 (de) * 2002-12-20 2011-04-15 Glaxosmithkline Biolog Sa Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
EP1644048B1 (de) * 2003-05-05 2015-04-29 Johns Hopkins University Anti-krebs-dna-vakzine mit einer für plasmide kodierenden signalsequenz, mutiertes onkoprotein-antigen und hitzeschockprotein
BRPI0410562B8 (pt) 2003-05-22 2021-05-25 Fralunhofer Usa Inc proteína de veículo e seu método de produção em uma planta, ácido nucleico isolado, vetor de expressão e célula hospedeira
DE10347710B4 (de) * 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US7285386B2 (en) * 2003-10-29 2007-10-23 University Of New Mexico, And Educational Institution Of The State Of New Mexico RhPV as a model for HPV-induced cancers
DE10357677A1 (de) * 2003-12-10 2005-07-14 Greiner Bio-One Gmbh Primer und Sonden zum Nachweis genitaler HPV-Genotypen
WO2005090968A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
AU2005322960A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
US8252893B2 (en) * 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
RU2283128C1 (ru) * 2005-04-05 2006-09-10 Сергей Викторович Луценко Способ получения препарата белка из семейства стрессовых и препарат белка hsp70, полученный этим способом
RU2285537C1 (ru) * 2005-04-05 2006-10-20 Автономная некоммерческая организация "Институт молекулярной диагностики (АНО "ИнМоДи") Противоопухолевый пептидный препарат на основе фрагмента альфа-фетопротеина, его конъюгат, фармацевтическая композиция и способ лечения гормонзависимых опухолей
DE602006021408D1 (de) * 2005-04-27 2011-06-01 Univ Leiden Medical Ct Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien
RU2290204C1 (ru) * 2005-07-27 2006-12-27 Общество с ограниченной ответственностью "Аванген" Рекомбинантный гибридный белок, препарат для иммунотерапии на его основе и способ иммунотерапии рецидивирующего папилломатоза гортани
CA2616859C (en) * 2005-08-03 2015-04-14 Fraunhofer Usa, Inc. Compositions and methods for production of immunoglobulins
US7622121B2 (en) * 2005-09-21 2009-11-24 New York University Heat shock proteins from Mycobacterium leprae and uses thereof
WO2008048344A2 (en) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
JP2009526526A (ja) * 2006-02-13 2009-07-23 フラウンホーファー ユーエスエー， インコーポレイテッド インフルエンザ抗原、ワクチン組成物、および関連する方法
KR20080106434A (ko) * 2006-02-13 2008-12-05 프라운호퍼 유에스에이, 인코포레이티드 Ｈｐｖ 항원, 백신 조성물 및 관련된 방법
RU2316342C1 (ru) * 2006-03-31 2008-02-10 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Вакцинная композиция для профилактики и лечения онкологических заболеваний, рекомбинантная плазмидная днк, обеспечивающая синтез гибридного белка, способ его получения
BRPI0712729A2 (pt) * 2006-05-31 2013-07-02 Nventa Biopharmaceuticals Corp composiÇÕes hspe7 bioativas purificadas
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080311145A1 (en) * 2007-04-04 2008-12-18 Specigen, Inc. Protein cage immunotherapeutics
BRPI0810865A2 (pt) * 2007-04-28 2017-05-09 Fraunhofer Usa Inc antígenos de tripanossoma, composições vacinais, e métodos relacionados
WO2009009759A2 (en) 2007-07-11 2009-01-15 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
BRPI0815662A2 (pt) * 2007-08-20 2016-09-27 Fraunhofer Usa Inc vacinas, antígenos, composições, e métodos profilácticos e terapêuticos para gripe
US20090117140A1 (en) * 2007-09-26 2009-05-07 Mayumi Nakagawa Human papilloma virus dominant CD4 T cell epitopes and uses thereof
WO2009094006A2 (en) * 2007-10-25 2009-07-30 Wake Forest University Health Sciences Bordetella outer-membrane protein antigens and methods of making and using the same
US8475785B2 (en) 2008-03-03 2013-07-02 The University Of Miami Allogeneic cancer cell-based immunotherapy
WO2009117116A2 (en) 2008-03-20 2009-09-24 University Of Miami Heat shock protein gp96 vaccination and methods of using same
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
BRPI0921802A8 (pt) * 2008-10-31 2018-03-13 Novartis Ag uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo.
AU2009319048B2 (en) * 2008-11-28 2014-01-30 Novartis Ag Pharmaceutical combination comprising a Hsp 90 inhibitor and a mTOR inhibitor
US8530431B2 (en) 2009-03-23 2013-09-10 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
US11963716B2 (en) 2010-07-19 2024-04-23 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
US9662510B2 (en) 2010-07-19 2017-05-30 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
RU2438652C1 (ru) * 2010-12-10 2012-01-10 Закрытое Акционерное Общество "Велес Фарма" Средство для лечения заболеваний шейки матки, ассоциированных с вирусом папилломы человека, в виде вагинального раствора для орошения, набор и способ его получения
RU2438702C1 (ru) * 2010-12-10 2012-01-10 Закрытое Акционерное Общество "Велес Фарма" Средство для лечения заболеваний шейки матки, ассоциированных с вирусом папилломы человека, в виде вагинальных капсул
RU2438703C1 (ru) * 2010-12-10 2012-01-10 Закрытое Акционерное Общество "Велес Фарма" Средство для лечения заболеваний шейки матки, ассоциированных с вирусом папилломы человека, в виде вагинального суппозитория
JP2014508762A (ja) * 2011-02-23 2014-04-10 ユニバーシティー オブ マイアミ ＳＩＶ／ＨＩＶからの防御を目的とする、組合せ細胞ベースのｇｐ９６−Ｉｇ−ＳＩＶ／ＨＩＶ、組換えｇｐ１２０タンパク質のワクチン接種
US9028884B2 (en) 2013-08-13 2015-05-12 Preventamedics LLC Medical delivery devices and methods for applying a barrier composition to a targeted skin surface
AU2014329393B2 (en) 2013-10-04 2020-04-30 Pin Pharma, Inc. Immunostimulatory HIV Tat derivative polypeptides for use in cancer treatment
GB2541749B (en) 2015-08-31 2020-12-09 Emblation Ltd An interference suppression apparatus and method
US11497926B2 (en) 2016-08-08 2022-11-15 Emblation Limited Method and apparatus for the treatment, management and/or control of pain
AU2018242490A1 (en) 2017-03-28 2019-11-14 Emblation Limited Stenosis treatment
CN118370809A (zh) * 2017-04-03 2024-07-23 百欧恩泰美国公司 蛋白质抗原及其用途
CN108409866A (zh) * 2018-01-23 2018-08-17 合肥瑞城生生物科技有限公司 一种用于治疗和预防人乳头瘤病毒感染及相关疾病的多表位组合肽
JP7546566B2 (ja) 2018-08-06 2024-09-06 ニールセン、バイオサイエンシズ、インコーポレイテッド 疣贅の治療
EP3909612A1 (de) * 2020-05-12 2021-11-17 Life Science Inkubator Betriebs GmbH & Co. KG Zusammensetzung von nanopartikeln
CN114478712B (zh) * 2022-03-29 2022-09-23 深圳吉诺因生物科技有限公司 Hpv抗原表位及其鉴定方法、应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666847A (en) * 1981-01-16 1987-05-19 Collaborative Research, Inc. Recombinant DNA means and method
DK172882B1 (da) 1983-02-07 1999-09-06 Rothwell Property Ltd DNA indeholdende udtrykkelseskontrolregion fra et eukaryot varmechokproteingen, vektor og eukaryot celle indeholdende DNA'e
US4797359A (en) * 1983-05-10 1989-01-10 Board Of Regents, The University Of Texas System Heat shock regulated production of selected and fused proteins in yeast
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
US4918164A (en) * 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4784941A (en) * 1985-04-08 1988-11-15 Genetic Systems Corporation Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV
AU6713287A (en) 1986-01-06 1987-07-09 F. Hoffmann-La Roche & Co. Expression of htlv-iii gag-gene
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4906742A (en) 1986-07-31 1990-03-06 Whitehead Institute For Biomedical Research Encoding antigens of M. Leprae
US6007806A (en) 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
NL8701163A (nl) 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
EP0345299A1 (de) 1987-02-02 1989-12-13 Whitehead Institute For Biomedical Research Mycobacterium tuberculosis-gene, kodierend für proteinantigene
US4952395A (en) 1987-02-26 1990-08-28 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US4918166A (en) 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
US5256767A (en) * 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
NL8703107A (nl) 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
US5204259A (en) * 1988-05-06 1993-04-20 Pharmacia Genetic Engineering, Inc. Methods and systems for producing HIV antigens
ATE127345T1 (de) 1988-06-15 1995-09-15 Whitehead Biomedical Inst Stressproteine und verwendungen dafür.
US5858646A (en) 1989-02-23 1999-01-12 University Of Ottawa Modified HIV-pol polypeptide having immunological activity for use as diagnostic reagent
US5114844A (en) 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
AU5848090A (en) 1989-06-19 1991-01-08 Whitehead Institute For Biomedical Research Vector-mediated genomic insertion and expression of dna in bcg
GB8919321D0 (en) 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
AU660430B2 (en) 1990-11-08 1995-06-29 Stanford Rook Limited Mycobacterium as adjuvant for antigens
GB2251186A (en) 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
EP0521220A1 (de) 1991-06-14 1993-01-07 Institut Pasteur Immunogene rekombinante Actinomycetale
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5580563A (en) 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
GB9211736D0 (en) 1992-06-03 1992-07-15 Univ Cardiff Allergic treatment
US5736146A (en) 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
PT700445E (pt) 1993-06-04 2002-07-31 Whitehead Biomedical Inst Proteinas de stress e suas utilizacoes
US5404142A (en) 1993-08-05 1995-04-04 Analog Devices, Incorporated Data-directed scrambler for multi-bit noise shaping D/A converters
ATE303160T1 (de) * 1993-08-11 2005-09-15 Jenner Technologies Impfstoff gegen prostatakrebs
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
IL109790A0 (en) 1994-05-25 1994-08-26 Yeda Res & Dev Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
GB9419979D0 (en) 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
AU4727296A (en) 1995-02-24 1996-09-11 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
WO1997006821A1 (en) 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
WO1997026910A2 (de) 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren
WO1998004706A1 (en) * 1996-07-29 1998-02-05 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
AU736318B2 (en) 1996-11-26 2001-07-26 Nventa Biopharmaceuticals Corporation Immune responses using compositions containing stress proteins
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
WO1998035705A1 (en) 1997-02-18 1998-08-20 Whitehead Institute For Biomedical Research Use of heat shock proteins to deliver moieties into cells
BR9812272A (pt) * 1997-08-05 2000-07-18 Stressgen Biotechnologies Corp Respostas imunológicas contra antìgenos de hpv, eliciadas por composições que compreendem um antìgeno de hpv e uma proteìna de tensão ou um vetor de expressão capaz de expressar essas proteìnas
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
CN1248631A (zh) * 1998-09-24 2000-03-29 周国庆 一种免疫预防和免疫治疗性病和癌症的融合蛋白
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
US6497880B1 (en) * 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
EP1196772A2 (de) 1999-07-08 2002-04-17 Stressgen Biotechnologies Corporation Induktion einer th1-vermittelten immunantwort in vitro
EP1218030A4 (de) 1999-09-10 2004-09-15 Univ Fordham Methoden und zusammensetzungen zur behandlung und prävention von transplantatabstossung durch verwendung von hitzeschockproteinen
US20010034042A1 (en) 2000-01-20 2001-10-25 Srivastava Pramod K. Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
AU2001229592A1 (en) 2000-01-21 2001-07-31 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
AU2001229597A1 (en) 2000-01-21 2001-07-31 University Of Connecticut Health Center Compositions and methods to treat neurodegenerative disorders
AU2001227960A1 (en) 2000-01-21 2001-07-31 University Of Connecticut Health Center Heat shock/stress protein complexes as vaccines against neurodegenerative disorders
HRP20021015A2 (en) * 2000-06-26 2004-02-29 Stressgen Biotechnologies Corp Human papilloma virus treatment

Also Published As

Publication number Publication date
HUP0301308A2 (hu) 2003-08-28
DE60119734D1 (de) 2006-06-22
NO20026044L (no) 2003-02-20
KR20030025939A (ko) 2003-03-29
US20040235741A1 (en) 2004-11-25
US20020110566A1 (en) 2002-08-15
CY1105389T1 (el) 2010-04-28
CN100441223C (zh) 2008-12-10
WO2002000242A2 (en) 2002-01-03
EP1296711B1 (de) 2006-05-17
SK18362002A3 (sk) 2004-02-03
US20080063661A1 (en) 2008-03-13
US7211411B2 (en) 2007-05-01
DK1296711T3 (da) 2006-08-28
ZA200210211B (en) 2004-03-17
HRP20021015A2 (en) 2004-02-29
HUP0301308A3 (en) 2010-01-28
NO20026044D0 (no) 2002-12-16
EE200200709A (et) 2004-08-16
PT1296711E (pt) 2006-08-31
US7754449B2 (en) 2010-07-13
KR100919266B1 (ko) 2009-09-30
ES2263637T3 (es) 2006-12-16
EP1296711A2 (de) 2003-04-02
US6797491B2 (en) 2004-09-28
MXPA02012858A (es) 2004-04-20
AU2006203436A1 (en) 2006-08-31
WO2002000242A3 (en) 2002-10-03
US20030170268A1 (en) 2003-09-11
KR20080075560A (ko) 2008-08-18
CA2413543A1 (en) 2002-01-03
CN1678344A (zh) 2005-10-05
CZ20024154A3 (cs) 2003-08-13
PL359930A1 (en) 2004-09-06
AU7144901A (en) 2002-01-08
DE60119734T2 (de) 2007-04-26
IL153474A0 (en) 2003-07-06
AU2001271449B2 (en) 2006-08-24
WO2002000242A8 (en) 2003-03-13
JP2004512264A (ja) 2004-04-22
RU2282461C2 (ru) 2006-08-27
BR0111956A (pt) 2003-05-13
NZ523408A (en) 2006-02-24

Similar Documents

Publication Publication Date Title
ATE326236T1 (de) Hpv-e7 zur behandlung von menschlichem papillomavirus
DE60105424D1 (de) Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
EP1385466A4 (de) Onkolytische virustherapie
BR0308444A (pt) Composição de vacina, método de produção de vacina, uso de uma mistura de vlps de hpv 16, hpv 18, hvp 31 e hpv 45, método de prevenção da infecção por hpv ou tratamento de doença relacionada com a infecção por hpv
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
EP1246644A4 (de) Induzierung zellulärer immunantworten auf humanen papillomavirus unter verwendung von peptiden und nukleinsäure-zusammensetzungen
DE69535758D1 (de) Lipid-analoge zur behandlung von viralen infektionen
CY1108147T1 (el) Εμβολιο κατα των σεξουαλικως μεταδιδομενων νοσων
DE69533673D1 (de) Behandlung und prävention von helicobacter-infektionen
EA200701633A1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
AUPQ761200A0 (en) Compositions and methods for treatment of mucosal infections
ATE425187T1 (de) Materialien und methoden zur behandlung von hepatitis c
ATE136468T1 (de) Impfstoff zur behandlung von hsv
AU4149699A (en) Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses
DE69933891D1 (de) Behandlung von papillomavirus-infektionen
ATE206456T1 (de) Impstoff gegen krankheitserreger, zusammensetzung zur behandlung und vorbeugung von hiv infektionen
ES2014042A6 (es) Un procedimiento para la preparacion de una composicion de 1-(2'-desoxi -2' fluor -b- d- arabinofuranosil) -5-etiluracilo.
DE60002172D1 (de) Verwendung von (1r,4s)-4-(6-amino-9h-purin-9-yl)-2-cyclopenten-1-methanol in hbv
RU98117264A (ru) Способ инактивации вируса иммунодефицита человека и других вирусов в плазме крови человека с сохранением функциональной активности белков плазмы крови
SU1739559A1 (ru) Штамм вируса aphtae epizooticae типа o, используемый для изготовления диагностических сывороток и антигенных препаратов

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1296711

Country of ref document: EP

REN Ceased due to non-payment of the annual fee